Loading...
NASDAQ: CRMD
CorMedix Inc.
Healthcare · Biotechnology
Market Cap
$502.22M
52w High
$17.43
52w Low
$5.60
P/E
3.07
Volume
306.83K
Outstanding Shares
79.05M
Company profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
CEOJoseph Todisco
SectorHealthcare
IndustryBiotechnology
Employees64
IPO dateMay 13, 2010
Valuation
Forward P/E—
EV/EBITDA5.09
Enterprise value$840.84M
Stock splits
Mar 26, 20191:5
Profitability & growth
Revenue growth312.1%
Gross margin88.46%▼4.53%vs FY2024
Operating margin48.17%▲193.66%vs FY2024
ROE40.23%▲289.95%vs FY2024
Analyst consensus
RatingBuy
Target price$13.75▲116.43%
6
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
View
EPS
Actual vs estimate by quarter
Q1FY25
ActualEst.
$0.30
$0.25
Q3FY25
ActualEst.
$0.57
$0.48
Q4FY25
ActualEst.
$0.61
$0.82
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q1FY25
ActualEst.
$39.08M
$29.88M
Q3FY25
ActualEst.
$104.28M
$127.02M
Q4FY25
ActualEst.
$128.62M
$108.7M
Q1FY26
Next Est.
—